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high risk to be non compliant. Patients declaring good compli-
ance, aged <77.5, with a good patient-clinician relationship were
likely to be compliant. CONCLUSIONS: When medical data
were not associated with compliance, patient reported outcome
might help at identifying glaucoma treatment compliance issues.
Treatment compliance is a complex concept, including several
dimensions with interactions. EDSQ demonstrated some abilities
at identifying non compliant patients. Age, declared compliance
and satisfaction with patient-clinician relationship are dimen-
sions that would be worth being explored before switching a
glaucoma treatment due to lack of intra-ocular pressure control.
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OBJECTIVES: It has long been suspected that treatment compli-
ance is affected by HRQoL. The aim of this study is to assess how
compliance is related to GSS scores and other treatment variables
in Glaucoma. METHODS: An observational study was carried
out gathering information on the Spanish version of the Glau-
coma Symptom Scale (GSS), three compliance scales (Morisky-
Green, Haynes-Sackett, & Batalla) and information about
disease severity and treatment. Concordance between adherence
scales was ﬁrst assessed. Using the Morisky-Green score as target
criteria, a segmentation tree was tested in order to forecast
compliance probability. CHAID growing algorithm was used.
RESULTS: A sample of 367 patients was recruited with an
average age of 68 (12.1) years from which 57% were females.
Most patients (87.7%) were diagnosed of glaucoma, 10.5% were
diagnosed of glaucoma and severe PIO and 1.8% presented sever
PIO alone. Agreement between adherence scales was poor with
a marked superiority of the Morisky-Green questionnaire. The
most signiﬁcant segmentation variable was GSS score, followed
by age, glaucoma severity (as assessed by the clinician), number
of treatment drugs, and number treatment of drops. Interaction
was found between number of drops and other variables in the
model. CONCLUSIONS: Using the tree model developed it is
possible to predict compliance probability. Self perceived sym-
ptom discomfort is found to be the best predictor. Additional
evidences of GSS construct validity as a measure of HRQoL have
been found.
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OBJECTIVES: To assess the effect of moderate to severe psoriasis
on quality of life (QoL) in Spanish patients. METHODS: An
observational study was conducted at 132 centers in Spain which
included 10 consecutive patients with moderate to severe psoria-
sis, deﬁned as: 1) patients with Body Surface Area >= 10 or 2)
Psoriasis Area and Severity Index (PASI) >= 10 or 3) Physician’s
Global Assessment >= 5 or 4) patients receiving systemic treat-
ment. Demographic data, medical history, treatments, occupa-
tional impairment, current state of the disease, resource use, and
QoL using the Dermatology Life Quality Index (DLQI) and other
questionnaires were collected. The DLQI is a self-administered
questionnaire with 10 questions measuring 6 domains: symp-
toms and feelings, daily activities, leisure, work and school,
personal relationships and treatment. DLQI results are shown as
mean scores and percentages (mean value obtained over the
maximum score of the domain). RESULTS: A total of 1307
(1141 with complete data) patients with moderate to severe
psoriasis fulﬁlled the inclusion criteria for the present study (38%
female), with a mean age of 45.7  0.9 (mean  SD) years, mean
duration of the disease of 23.3  2.3 years and mean PASI score
of 13.1  0.3. The mean DLQI score was 8.7  0.2, meaning a
moderate effect of psoriasis on patient life. Highest mean scores
(worst) were obtained in symptoms and feelings (2.7, 45%) and
treatment (1.0, 33%) domains and lowest mean scores were
obtained in personal relationships (1.1, 18%) and work and
school (0.7, 23%) domains. Mean scores for daily activities and
leisure were 1.7 (28%) and 1.6 (26%) respectively. CONCLU-
SIONS: Moderate to severe psoriasis has a negative impact on
patient QoL. A more intensive and integrated approach to these
patients should be considered to achieve a smaller impact of
psoriasis on patients’ quality of life.
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OBJECTIVES: To conﬁrm the reliability of quality-of-life (QOL)
assessments in a randomized controlled trial (RCT), we investi-
gated the changes in internal standards as a representative of
‘response shift (RS)’. METHODS: One-hundred and three
patients with age-related maculopathy in Japan were randomized
to the intervention group and the control group. The intervention
group received a standardized low vision care program for 6
months. For ethical considerations, low vision care was also
provided for applicants in the control group after 6 months. We
assessed visual function-related QOL using the Japanese version
of the 25-item National Eye Institute Visual Function Question-
naire (VFQ-25) at baseline, 6-, and 12-months. We asked the
patients to answer an additional questionnaire to investigate the
changes in internal standards at 6- and 12- months which
inquired about QOL at baseline (then-test). This questionnaire
included 7 items selected from the VFQ-25 as the representatives
of major 7 domains (general vision [GV], near vision [NV],
distance vision [DV], social function [SF], mental health [MH],
role limitations [RL], and dependency [DP]). RESULTS: Fifty-
four patients at 6-months and 52 patients at 12-months com-
pleted the then-test questionnaire in addition to the VFQ-25.
Regardless of the direction of change (improved or deteriorated)
in scores, the then-test results tended to decrease the difference
of the scores. That is, then-test scores tended to be higher than
baseline scores in the case of improvement, and tended to be
lower than baseline scores in the case of deterioration. The
statistically signiﬁcant difference was observed between pre- and
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